Clinical trials
Cancer Recurrence clinical trials
Below are recruiting cancer recurrence clinical trials, each written for real people, not researchers. We’re tracking 680 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05444478Recruiting
Microwave ablation plus lenvatinib for recurrent liver cancer
This trial tests whether combining heat treatment to kill liver tumors (microwave ablation) with the medicine lenvatinib can better control recurrent hepatocellular carcinoma (HCC). It may help shrink tumors or slow growth for people whose cancer has come back but who have limited tumor burden.
Changsha, HunanAges 18–75 - NCT05710848RecruitingPhase 1/Phase 2
Study drug for repeat bladder tumor surgery patients
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
Mesa, ArizonaAges 18 years+ - NCT07213934RecruitingPhase 1/Phase 2
Immunotherapy and radiation before surgery for recurrent head and neck cancer
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
Cincinnati, OhioAges 18 years+ - NCT05559879RecruitingPhase 1/Phase 2
Cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Birmingham, AlabamaAges 18 years+ - NCT05595590RecruitingPhase 2
Radiation plus immunotherapy for recurrent head and neck cancer
This study tests whether adding an immunotherapy medicine called tislelizumab to radiation can better control recurrent (coming back) head and neck squamous cell cancer. It is aimed at people whose cancer can’t be fully removed by surgery or can’t be safely removed.
Chengdu, SichuanAges 18–75 - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT04858880Recruiting
Personalized radiation for PSA rise after prostate surgery
This study tests a tailored (personalized) radiation plan for men whose PSA (“prostate blood test”) rises after prostate surgery but who have no detectable spread on scans. It may help control cancer growth by targeting the right area based on your situation.
JönköpingAges 18 years+ - NCT05104736RecruitingPhase 2
PT-112 for thymus gland tumors after prior chemotherapy
This trial studies PT-112, a new treatment, in people with thymoma or thymic carcinoma that has grown despite at least one prior platinum chemotherapy treatment. It may help shrink tumors or slow disease progression, especially when surgery is not possible.
Bethesda, MarylandAges 18–120 - NCT06185569Recruiting
French study on outcomes in HR+/HER2- early breast cancer patients with Oncotype DX
This study looks at how well treatments work for people with early-stage, hormone receptor-positive, HER2-negative breast cancer when the Oncotype DX test helps guide therapy. It aims to understand real-world outcomes in French patients.
BesançonAges 18 years+ - NCT06155396RecruitingPhase 2
Targeted drug combo for advanced cervical cancer
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Bengbu, AnhuiAges 18 years+ - NCT07631572Recruiting
Cesium implant radiation for recurrent cervical or uterine cancer
This study tests a type of internal radiation (cesium implant) to treat cancer that has come back in the vagina after previous pelvic radiation. The goal is to save the organ while treating the cancer.
Lexington, KentuckyAges 18 years+ - NCT06692166RecruitingPhase 3
New drug vs standard chemo for advanced cervical cancer
This trial tests a new drug called 9MW2821 against standard chemotherapy options for cervical cancer that has come back or spread. The goal is to see if the new drug works better than the usual treatments, and you must have already tried a platinum-based chemotherapy.
BeijingAges 18–75 - NCT07207070RecruitingPhase 3
New drug combination for PIK3CA-mutated breast cancer
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT07003074RecruitingPhase 3
New drug TQB2102 vs standard therapy for HER2+ breast cancer
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Hefei, AnhuiAges 18–75 - NCT06952660RecruitingPhase 4
Eye tests for people taking Tivdak for cervical cancer
This trial is for people with cervical cancer that has come back or spread and is getting worse after chemotherapy. It will check your eyes regularly while you take Tivdak to see how the drug affects them.
Phoenix, ArizonaAges 18 years+ - NCT06755515Enrolling by invitationPhase 2/Phase 3
Rulonilimab + Chemo for Advanced Cervical Cancer
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
Linyi, ShandongAges 18 years+ - NCT06518564RecruitingPhase 2
Avelumab and M1774 for ARID1A-mutated endometrial cancer
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06040970RecruitingPhase 1/Phase 2
Sacituzumab govitecan plus cisplatin for recurrent ovarian/endometrial cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
New York, New YorkAges 18 years+ - NCT05838521RecruitingPhase 2
IMMU-132 for cervical cancer that returned or did not go away
This trial studies IMMU-132 (sacituzumab govitecan) in people whose cervical cancer keeps coming back or stays after prior treatment. It aims to shrink tumors and improve outcomes after at least one chemotherapy has already been tried.
New Haven, ConnecticutAges 18 years+ - NCT04486352RecruitingPhase 1/Phase 2
Targeted therapy trial for recurrent or persistent endometrial cancer
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
Duarte, CaliforniaAges 18 years+ - NCT05022914Recruiting
PSMA PET/CT scan for PSA relapse after prostate surgery
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
FlorenceAges 18 years+ - NCT06957626Recruiting
Predicting polyp return after removal
This study aims to develop a tool using gut bacteria and metabolites to predict if high-risk colon polyps will come back after removal. If you are between 40 and 75 and have had certain types of colon polyps removed, you may be able to help us build better prediction methods.
BeijingAges 40–75 - NCT03246802Recruiting
HDR brachytherapy for prostate cancer that returned after prior radiation
This trial studies a targeted, high-dose form of radiation (HDR brachytherapy) for prostate cancer that has come back after earlier radiation treatment. It aims to treat a limited (one-area) recurrence while trying to avoid serious late side effects from repeat radiation.
Kelowna, British ColumbiaAges 45 years+
Hear when a new Cancer Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer recurrence?
- Yes. Clin2 currently lists 680 recruiting cancer recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.